Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentosan polysulfate sodium for Ross River virus-induced arthralgia
ACTRN12617000893303Phase 2Completed
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Aug 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ross River fever comparing Pentosan polysulfate sodium with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events including serious adverse events, Haematology safety changes and 1 more. Started Aug 2017; status: completed.
02
Drugs
pentosan polysulfate sodium
03
Conditions
Ross River fever
Beyond the preview
Go deeper on ACTRN12617000893303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000893303.